<?xml version="1.0" encoding="UTF-8"?>
<protein>
  <version>3.5</version>
  <creation_date>2013-01-15 19:07:46 -0700</creation_date>
  <update_date>2013-01-15 19:07:46 -0700</update_date>
  <accession>HMDBP02749</accession>
  <secondary_accessions>
    <accession>8254</accession>
  </secondary_accessions>
  <protein_type>Transporter</protein_type>
  <synonyms>
    <synonym>Intestinal H(+)/peptide cotransporter</synonym>
    <synonym>Oligopeptide transporter, small intestine isoform</synonym>
    <synonym>Peptide transporter 1</synonym>
  </synonyms>
  <gene_name>SLC15A1</gene_name>
  <general_function>Involved in transporter activity</general_function>
  <specific_function>Proton-coupled intake of oligopeptides of 2 to 4 amino acids with a preference for dipeptides. May constitute a major route for the absorption of protein digestion end-products</specific_function>
  <pathways>
  </pathways>
  <metabolite_associations>
    <metabolite>
      <accession>HMDB14324</accession>
      <name>Ramipril</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14343</accession>
      <name>Oseltamivir</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14419</accession>
      <name>Cefmetazole</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14559</accession>
      <name>Ampicillin</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14582</accession>
      <name>Ceftazidime</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14590</accession>
      <name>Loracarbef</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14599</accession>
      <name>Cefalotin</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14628</accession>
      <name>Dicloxacillin</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14635</accession>
      <name>Fosinopril</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14636</accession>
      <name>Cefotaxime</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14660</accession>
      <name>Trandolapril</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14675</accession>
      <name>Cefdinir</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14682</accession>
      <name>Benazepril</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14707</accession>
      <name>Cephalexin</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14716</accession>
      <name>Valaciclovir</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14722</accession>
      <name>Enalapril</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14809</accession>
      <name>Cefixime</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14024</accession>
      <name>2-Hydroxychlorpropamide</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14829</accession>
      <name>Moexipril</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14851</accession>
      <name>Oxacillin</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14869</accession>
      <name>Nateglinide</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14928</accession>
      <name>Perindopril</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14971</accession>
      <name>Cefaclor</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15019</accession>
      <name>Quinapril</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15135</accession>
      <name>Cyclacillin</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15151</accession>
      <name>Glyburide</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15186</accession>
      <name>Penicillin G</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15193</accession>
      <name>Amoxicillin</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15244</accession>
      <name>Cefuroxime</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15256</accession>
      <name>Tolbutamide</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15271</accession>
      <name>Cefadroxil</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15278</accession>
      <name>Cloxacillin</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15328</accession>
      <name>Captopril</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15343</accession>
      <name>Ceftriaxone</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00181</accession>
      <name>L-Dopa</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15427</accession>
      <name>Ceftizoxime</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15428</accession>
      <name>Cefradine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15433</accession>
      <name>Cilazapril</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15438</accession>
      <name>Spirapril</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15483</accession>
      <name>Cefepime</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15485</accession>
      <name>Ceftibuten</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15685</accession>
      <name>Azidocillin</name>
    </metabolite>
  </metabolite_associations>
  <go_classifications>
    <go_class>
      <category>function</category>
      <description>substrate-specific transporter activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>peptide transporter activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>oligopeptide transporter activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>transporter activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>establishment of localization</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>transport</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>peptide transport</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>oligopeptide transport</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>component</category>
      <description>membrane part</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>component</category>
      <description>intrinsic to membrane</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>component</category>
      <description>integral to membrane</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>component</category>
      <description>cell part</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>component</category>
      <description>membrane</description>
      <go_id/>
    </go_class>
  </go_classifications>
  <subcellular_locations>
    <subcellular_location>Membrane</subcellular_location>
    <subcellular_location>Multi-pass membrane protein</subcellular_location>
  </subcellular_locations>
  <gene_properties>
    <chromosome_location>Chromosome:1</chromosome_location>
    <locus>13q33-q34</locus>
    <gene_sequence>&gt;2127 bp
ATGGGAATGTCCAAATCACACAGTTTCTTTGGTTATCCCCTGAGCATCTTCTTCATCGTG
GTCAATGAGTTTTGCGAAAGATTTTCCTACTATGGAATGCGAGCAATCCTGATTCTGTAC
TTCACAAATTTCATCAGCTGGGATGATAACCTGTCCACCGCCATCTACCATACGTTTGTG
GCTCTGTGCTACCTGACGCCAATTCTCGGAGCTCTTATCGCCGACTCGTGGCTGGGAAAG
TTCAAGACCATTGTGTCGCTCTCCATTGTCTACACAATTGGACAAGCAGTCACCTCAGTA
AGCTCCATTAATGACCTCACAGACCACAACCATGATGGCACCCCCGACAGCCTTCCTGTG
CACGTGGTGCTGTCCTTGATCGGCCTGGCCCTGATAGCTCTCGGGACTGGAGGAATCAAA
CCCTGTGTGTCTGCGTTTGGTGGAGATCAGTTTGAAGAGGGCCAGGAGAAACAAAGAAAC
AGATTTTTTTCCATCTTTTACTTGGCTATTAATGCTGGAAGTTTGCTTTCCACAATCATC
ACACCCATGCTCAGAGTTCAACAATGTGGAATTCACAGTAAACAAGCTTGTTACCCACTG
GCCTTTGGGGTTCCTGCTGCTCTCATGGCTGTAGCCCTGATTGTGTTTGTCCTTGGCAGT
GGGATGTACAAGAAGTTCAAGCCACAGGGCAACATCATGGGTAAAGTGGCCAAGTGCATC
GGTTTTGCCATCAAAAATAGATTTAGGCATCGGAGTAAGGCATTTCCCAAGAGGGAGCAC
TGGCTGGACTGGGCTAAAGAGAAATACGATGAGCGGCTCATCTCCCAAATTAAGATGGTT
ACGAGGGTGATGTTCCTGTATATTCCACTCCCAATGTTCTGGGCCTTGTTTGACCAGCAG
GGCTCCAGGTGGACACTGCAGGCAACAACTATGTCCGGGAAAATCGGAGCTCTTGAAATT
CAGCCCGATCAGATGCAGACCGTGAACGCCATCCTGATCGTGATCATGGTCCCGATCTTC
GATGCTGTGCTGTACCCTCTCATTGCAAAATGTGGCTTCAATTTCACCTCCTTGAAGAAG
ATGGCAGTTGGCATGGTCCTGGCCTCCATGGCCTTTGTGGTGGCTGCCATCGTGCAGGTG
GAAATCGATAAAACTCTTCCAGTCTTCCCCAAAGGAAACGAAGTCCAAATTAAAGTTTTG
AATATAGGAAACAATACCATGAATATATCTCTTCCTGGAGAGATGGTGACACTTGGCCCA
ATGTCTCAAACAAATGCATTTATGACTTTTGATGTAAACAAACTGACAAGGATAAACATT
TCTTCTCCTGGATCACCAGTCACTGCTGTAACTGACGACTTCAAGCAGGGCCAACGCCAC
ACGCTTCTAGTGTGGGCCCCCAATCACTACCAGGTGGTAAAGGATGGTCTTAACCAGAAG
CCAGAAAAAGGGGAAAATGGAATCAGATTTGTAAATACTTTTAACGAGCTCATCACCATC
ACAATGAGTGGGAAAGTTTATGCAAACATCAGCAGCTACAATGCCAGCACATACCAGTTT
TTTCCTTCTGGCATAAAAGGCTTCACAATAAGCTCAACAGAGATTCCGCCACAATGTCAA
CCTAATTTCAATACTTTCTACCTTGAATTTGGTAGTGCTTATACCTATATAGTCCAAAGG
AAGAATGACAGCTGCCCTGAAGTGAAGGTGTTTGAAGATATTTCAGCCAACACAGTTAAC
ATGGCTCTGCAAATCCCGCAGTATTTTCTTCTCACCTGTGGCGAAGTGGTCTTCTCTGTC
ACGGGATTGGAATTCTCATATTCTCAGGCTCCTTCCAACATGAAGTCGGTGCTTCAGGCA
GGATGGCTGCTGACCGTGGCTGTTGGCAACATCATTGTGCTCATCGTGGCAGGGGCAGGC
CAGTTCAGCAAACAGTGGGCCGAGTACATTCTATTTGCCGCGTTGCTTCTGGTCGTCTGT
GTAATTTTTGCCATCATGGCTCGGTTCTATACTTACATCAACCCAGCGGAGATCGAAGCT
CAATTTGATGAGGATGAAAAGAAAAACAGACTGGAAAAGAGTAACCCATATTTCATGTCA
GGGGCCAATTCACAGAAACAGATGTGA</gene_sequence>
  </gene_properties>
  <protein_properties>
    <residue_number>708</residue_number>
    <molecular_weight>78805.3</molecular_weight>
    <theoretical_pi>8.64</theoretical_pi>
    <pfams>
      <pfam>
        <name>PTR2</name>
        <pfam_id>PF00854</pfam_id>
      </pfam>
    </pfams>
    <transmembrane_regions>
      <region>1-21</region>
      <region>54-74</region>
      <region>83-103</region>
      <region>119-139</region>
      <region>162-182</region>
      <region>199-219</region>
      <region>277-297</region>
      <region>328-348</region>
      <region>362-382</region>
      <region>585-605</region>
      <region>620-640</region>
      <region>646-666</region>
    </transmembrane_regions>
    <signal_regions>
      <region>None</region>
    </signal_regions>
    <protein_sequence>&gt;Solute carrier family 15 member 1
MGMSKSHSFFGYPLSIFFIVVNEFCERFSYYGMRAILILYFTNFISWDDNLSTAIYHTFV
ALCYLTPILGALIADSWLGKFKTIVSLSIVYTIGQAVTSVSSINDLTDHNHDGTPDSLPV
HVVLSLIGLALIALGTGGIKPCVSAFGGDQFEEGQEKQRNRFFSIFYLAINAGSLLSTII
TPMLRVQQCGIHSKQACYPLAFGVPAALMAVALIVFVLGSGMYKKFKPQGNIMGKVAKCI
GFAIKNRFRHRSKAFPKREHWLDWAKEKYDERLISQIKMVTRVMFLYIPLPMFWALFDQQ
GSRWTLQATTMSGKIGALEIQPDQMQTVNAILIVIMVPIFDAVLYPLIAKCGFNFTSLKK
MAVGMVLASMAFVVAAIVQVEIDKTLPVFPKGNEVQIKVLNIGNNTMNISLPGEMVTLGP
MSQTNAFMTFDVNKLTRINISSPGSPVTAVTDDFKQGQRHTLLVWAPNHYQVVKDGLNQK
PEKGENGIRFVNTFNELITITMSGKVYANISSYNASTYQFFPSGIKGFTISSTEIPPQCQ
PNFNTFYLEFGSAYTYIVQRKNDSCPEVKVFEDISANTVNMALQIPQYFLLTCGEVVFSV
TGLEFSYSQAPSNMKSVLQAGWLLTVAVGNIIVLIVAGAGQFSKQWAEYILFAALLLVVC
VIFAIMARFYTYINPAEIEAQFDEDEKKNRLEKSNPYFMSGANSQKQM</protein_sequence>
  </protein_properties>
  <genbank_protein_id/>
  <uniprot_id>P46059</uniprot_id>
  <uniprot_name>S15A1_HUMAN</uniprot_name>
  <pdb_ids>
  </pdb_ids>
  <genbank_gene_id>U13173</genbank_gene_id>
  <genecard_id>SLC15A1</genecard_id>
  <geneatlas_id>SLC15A1</geneatlas_id>
  <hgnc_id>HGNC:10920</hgnc_id>
  <general_references>
    <reference>
      <reference_text>Liang R, Fei YJ, Prasad PD, Ramamoorthy S, Han H, Yang-Feng TL, Hediger MA, Ganapathy V, Leibach FH: Human intestinal H+/peptide cotransporter. Cloning, functional expression, and chromosomal localization. J Biol Chem. 1995 Mar 24;270(12):6456-63.</reference_text>
      <pubmed_id>7896779</pubmed_id>
    </reference>
    <reference>
      <reference_text>Dunham A, Matthews LH, Burton J, Ashurst JL, Howe KL, Ashcroft KJ, Beare DM, Burford DC, Hunt SE, Griffiths-Jones S, Jones MC, Keenan SJ, Oliver K, Scott CE, Ainscough R, Almeida JP, Ambrose KD, Andrews DT, Ashwell RI, Babbage AK, Bagguley CL, Bailey J, Bannerjee R, Barlow KF, Bates K, Beasley H, Bird CP, Bray-Allen S, Brown AJ, Brown JY, Burrill W, Carder C, Carter NP, Chapman JC, Clamp ME, Clark SY, Clarke G, Clee CM, Clegg SC, Cobley V, Collins JE, Corby N, Coville GJ, Deloukas P, Dhami P, Dunham I, Dunn M, Earthrowl ME, Ellington AG, Faulkner L, Frankish AG, Frankland J, French L, Garner P, Garnett J, Gilbert JG, Gilson CJ, Ghori J, Grafham DV, Gribble SM, Griffiths C, Hall RE, Hammond S, Harley JL, Hart EA, Heath PD, Howden PJ, Huckle EJ, Hunt PJ, Hunt AR, Johnson C, Johnson D, Kay M, Kimberley AM, King A, Laird GK, Langford CJ, Lawlor S, Leongamornlert DA, Lloyd DM, Lloyd C, Loveland JE, Lovell J, Martin S, Mashreghi-Mohammadi M, McLaren SJ, McMurray A, Milne S, Moore MJ, Nickerson T, Palmer SA, Pearce AV, Peck AI, Pelan S, Phillimore B, Porter KM, Rice CM, Searle S, Sehra HK, Shownkeen R, Skuce CD, Smith M, Steward CA, Sycamore N, Tester J, Thomas DW, Tracey A, Tromans A, Tubby B, Wall M, Wallis JM, West AP, Whitehead SL, Willey DL, Wilming L, Wray PW, Wright MW, Young L, Coulson A, Durbin R, Hubbard T, Sulston JE, Beck S, Bentley DR, Rogers J, Ross MT: The DNA sequence and analysis of human chromosome 13.  Nature. 2004 Apr 1;428(6982):522-8.</reference_text>
      <pubmed_id>15057823</pubmed_id>
    </reference>
    <reference>
      <reference_text>Gerhard DS, Wagner L, Feingold EA, Shenmen CM, Grouse LH, Schuler G, Klein SL, Old S, Rasooly R, Good P, Guyer M, Peck AM, Derge JG, Lipman D, Collins FS, Jang W, Sherry S, Feolo M, Misquitta L, Lee E, Rotmistrovsky K, Greenhut SF, Schaefer CF, Buetow K, Bonner TI, Haussler D, Kent J, Kiekhaus M, Furey T, Brent M, Prange C, Schreiber K, Shapiro N, Bhat NK, Hopkins RF, Hsie F, Driscoll T, Soares MB, Casavant TL, Scheetz TE, Brown-stein MJ, Usdin TB, Toshiyuki S, Carninci P, Piao Y, Dudekula DB, Ko MS, Kawakami K, Suzuki Y, Sugano S, Gruber CE, Smith MR, Simmons B, Moore T, Waterman R, Johnson SL, Ruan Y, Wei CL, Mathavan S, Gunaratne PH, Wu J, Garcia AM, Hulyk SW, Fuh E, Yuan Y, Sneed A, Kowis C, Hodgson A, Muzny DM, McPherson J, Gibbs RA, Fahey J, Helton E, Ketteman M, Madan A, Rodrigues S, Sanchez A, Whiting M, Madari A, Young AC, Wetherby KD, Granite SJ, Kwong PN, Brinkley CP, Pearson RL, Bouffard GG, Blakesly RW, Green ED, Dickson MC, Rodriguez AC, Grimwood J, Schmutz J, Myers RM, Butterfield YS, Griffith M, Griffith OL, Krzywinski MI, Liao N, Morin R, Palmquist D, Petrescu AS, Skalska U, Smailus DE, Stott JM, Schnerch A, Schein JE, Jones SJ, Holt RA, Baross A, Marra MA, Clifton S, Makowski KA, Bosak S, Malek J: The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC). Genome Res. 2004 Oct;14(10B):2121-7.</reference_text>
      <pubmed_id>15489334</pubmed_id>
    </reference>
    <reference>
      <reference_text>Saito S, Iida A, Sekine A, Ogawa C, Kawauchi S, Higuchi S, Nakamura Y: Catalog of 238 variations among six human genes encoding solute carriers ( hSLCs) in the Japanese population. J Hum Genet. 2002;47(11):576-84.</reference_text>
      <pubmed_id>12436193</pubmed_id>
    </reference>
    <reference>
      <reference_text>Anderle P, Nielsen CU, Pinsonneault J, Krog PL, Brodin B, Sadee W: Genetic variants of the human dipeptide transporter PEPT1.  J Pharmacol Exp Ther. 2006 Feb;316(2):636-46. Epub 2005 Oct 28.</reference_text>
      <pubmed_id>16258023</pubmed_id>
    </reference>
  </general_references>
  <metabolite_references>
    <metabolite_reference>
      <metabolite>
        <name>Ramipril</name>
        <accession>HMDB14324</accession>
      </metabolite>
      <reference>
        <reference_text>Knutter I, Wollesky C, Kottra G, Hahn MG, Fischer W, Zebisch K, Neubert RH, Daniel H, Brandsch M: Transport of angiotensin-converting enzyme inhibitors by H+/peptide transporters revisited. J Pharmacol Exp Ther. 2008 Nov;327(2):432-41. Epub 2008 Aug 19.</reference_text>
        <pubmed_id>18713951</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Oseltamivir</name>
        <accession>HMDB14343</accession>
      </metabolite>
      <reference>
        <reference_text>Ogihara T, Kano T, Wagatsuma T, Wada S, Yabuuchi H, Enomoto S, Morimoto K, Shirasaka Y, Kobayashi S, Tamai I: Oseltamivir (tamiflu) is a substrate of peptide transporter 1.  Drug Metab Dispos. 2009 Aug;37(8):1676-81. Epub 2009 May 13.</reference_text>
        <pubmed_id>19439487</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Cefmetazole</name>
        <accession>HMDB14419</accession>
      </metabolite>
      <reference>
        <reference_text>Luckner P, Brandsch M: Interaction of 31 beta-lactam antibiotics with the H+/peptide symporter PEPT2: analysis of affinity constants and comparison with PEPT1. Eur J Pharm Biopharm. 2005 Jan;59(1):17-24.</reference_text>
        <pubmed_id>15567297</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Ampicillin</name>
        <accession>HMDB14559</accession>
      </metabolite>
      <reference>
        <reference_text>Covitz KM, Amidon GL, Sadee W: Human dipeptide transporter, hPEPT1, stably transfected into Chinese hamster ovary cells. Pharm Res. 1996 Nov;13(11):1631-4.</reference_text>
        <pubmed_id>8956326</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Ampicillin</name>
        <accession>HMDB14559</accession>
      </metabolite>
      <reference>
        <reference_text>Guo A, Hu P, Balimane PV, Leibach FH, Sinko PJ: Interactions of a nonpeptidic drug, valacyclovir, with the human intestinal peptide transporter (hPEPT1) expressed in a mammalian cell line. J Pharmacol Exp Ther. 1999 Apr;289(1):448-54.</reference_text>
        <pubmed_id>10087037</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Ampicillin</name>
        <accession>HMDB14559</accession>
      </metabolite>
      <reference>
        <reference_text>Luckner P, Brandsch M: Interaction of 31 beta-lactam antibiotics with the H+/peptide symporter PEPT2: analysis of affinity constants and comparison with PEPT1. Eur J Pharm Biopharm. 2005 Jan;59(1):17-24.</reference_text>
        <pubmed_id>15567297</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Ampicillin</name>
        <accession>HMDB14559</accession>
      </metabolite>
      <reference>
        <reference_text>Terada T, Saito H, Mukai M, Inui K: Recognition of beta-lactam antibiotics by rat peptide transporters, PEPT1 and PEPT2, in LLC-PK1 cells. Am J Physiol. 1997 Nov;273(5 Pt 2):F706-11.</reference_text>
        <pubmed_id>9374833</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Ceftazidime</name>
        <accession>HMDB14582</accession>
      </metabolite>
      <reference>
        <reference_text>Ganapathy ME, Huang W, Rajan DP, Carter AL, Sugawara M, Iseki K, Leibach FH, Ganapathy V: beta-lactam antibiotics as substrates for OCTN2, an organic cation/carnitine transporter. J Biol Chem. 2000 Jan 21;275(3):1699-707.</reference_text>
        <pubmed_id>10636865</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Ceftazidime</name>
        <accession>HMDB14582</accession>
      </metabolite>
      <reference>
        <reference_text>Luckner P, Brandsch M: Interaction of 31 beta-lactam antibiotics with the H+/peptide symporter PEPT2: analysis of affinity constants and comparison with PEPT1. Eur J Pharm Biopharm. 2005 Jan;59(1):17-24.</reference_text>
        <pubmed_id>15567297</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Loracarbef</name>
        <accession>HMDB14590</accession>
      </metabolite>
      <reference>
        <reference_text>Wenzel U, Gebert I, Weintraut H, Weber WM, Clauss W, Daniel H: Transport characteristics of differently charged cephalosporin antibiotics in oocytes expressing the cloned intestinal peptide transporter PepT1 and in human intestinal Caco-2 cells. J Pharmacol Exp Ther. 1996 May;277(2):831-9.</reference_text>
        <pubmed_id>8627565</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Cefalotin</name>
        <accession>HMDB14599</accession>
      </metabolite>
      <reference>
        <reference_text>Luckner P, Brandsch M: Interaction of 31 beta-lactam antibiotics with the H+/peptide symporter PEPT2: analysis of affinity constants and comparison with PEPT1. Eur J Pharm Biopharm. 2005 Jan;59(1):17-24.</reference_text>
        <pubmed_id>15567297</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Dicloxacillin</name>
        <accession>HMDB14628</accession>
      </metabolite>
      <reference>
        <reference_text>Luckner P, Brandsch M: Interaction of 31 beta-lactam antibiotics with the H+/peptide symporter PEPT2: analysis of affinity constants and comparison with PEPT1. Eur J Pharm Biopharm. 2005 Jan;59(1):17-24.</reference_text>
        <pubmed_id>15567297</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Fosinopril</name>
        <accession>HMDB14635</accession>
      </metabolite>
      <reference>
        <reference_text>Knutter I, Wollesky C, Kottra G, Hahn MG, Fischer W, Zebisch K, Neubert RH, Daniel H, Brandsch M: Transport of angiotensin-converting enzyme inhibitors by H+/peptide transporters revisited. J Pharmacol Exp Ther. 2008 Nov;327(2):432-41. Epub 2008 Aug 19.</reference_text>
        <pubmed_id>18713951</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Cefotaxime</name>
        <accession>HMDB14636</accession>
      </metabolite>
      <reference>
        <reference_text>Luckner P, Brandsch M: Interaction of 31 beta-lactam antibiotics with the H+/peptide symporter PEPT2: analysis of affinity constants and comparison with PEPT1. Eur J Pharm Biopharm. 2005 Jan;59(1):17-24.</reference_text>
        <pubmed_id>15567297</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Trandolapril</name>
        <accession>HMDB14660</accession>
      </metabolite>
      <reference>
        <reference_text>Knutter I, Wollesky C, Kottra G, Hahn MG, Fischer W, Zebisch K, Neubert RH, Daniel H, Brandsch M: Transport of angiotensin-converting enzyme inhibitors by H+/peptide transporters revisited. J Pharmacol Exp Ther. 2008 Nov;327(2):432-41. Epub 2008 Aug 19.</reference_text>
        <pubmed_id>18713951</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Cefdinir</name>
        <accession>HMDB14675</accession>
      </metabolite>
      <reference>
        <reference_text>Ganapathy ME, Prasad PD, Mackenzie B, Ganapathy V, Leibach FH: Interaction of anionic cephalosporins with the intestinal and renal peptide transporters PEPT 1 and PEPT 2. Biochim Biophys Acta. 1997 Mar 13;1324(2):296-308.</reference_text>
        <pubmed_id>9092716</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Cefdinir</name>
        <accession>HMDB14675</accession>
      </metabolite>
      <reference>
        <reference_text>Terada T, Saito H, Mukai M, Inui K: Recognition of beta-lactam antibiotics by rat peptide transporters, PEPT1 and PEPT2, in LLC-PK1 cells. Am J Physiol. 1997 Nov;273(5 Pt 2):F706-11.</reference_text>
        <pubmed_id>9374833</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Cefdinir</name>
        <accession>HMDB14675</accession>
      </metabolite>
      <reference>
        <reference_text>Tsuji A: Transporter-mediated Drug Interactions.  Drug Metab Pharmacokinet. 2002;17(4):253-74.</reference_text>
        <pubmed_id>15618677</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Benazepril</name>
        <accession>HMDB14682</accession>
      </metabolite>
      <reference>
        <reference_text>Knutter I, Wollesky C, Kottra G, Hahn MG, Fischer W, Zebisch K, Neubert RH, Daniel H, Brandsch M: Transport of angiotensin-converting enzyme inhibitors by H+/peptide transporters revisited. J Pharmacol Exp Ther. 2008 Nov;327(2):432-41. Epub 2008 Aug 19.</reference_text>
        <pubmed_id>18713951</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Cephalexin</name>
        <accession>HMDB14707</accession>
      </metabolite>
      <reference>
        <reference_text>Liang R, Fei YJ, Prasad PD, Ramamoorthy S, Han H, Yang-Feng TL, Hediger MA, Ganapathy V, Leibach FH: Human intestinal H+/peptide cotransporter. Cloning, functional expression, and chromosomal localization. J Biol Chem. 1995 Mar 24;270(12):6456-63.</reference_text>
        <pubmed_id>7896779</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Cephalexin</name>
        <accession>HMDB14707</accession>
      </metabolite>
      <reference>
        <reference_text>Wenzel U, Gebert I, Weintraut H, Weber WM, Clauss W, Daniel H: Transport characteristics of differently charged cephalosporin antibiotics in oocytes expressing the cloned intestinal peptide transporter PepT1 and in human intestinal Caco-2 cells. J Pharmacol Exp Ther. 1996 May;277(2):831-9.</reference_text>
        <pubmed_id>8627565</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Cephalexin</name>
        <accession>HMDB14707</accession>
      </metabolite>
      <reference>
        <reference_text>Covitz KM, Amidon GL, Sadee W: Human dipeptide transporter, hPEPT1, stably transfected into Chinese hamster ovary cells. Pharm Res. 1996 Nov;13(11):1631-4.</reference_text>
        <pubmed_id>8956326</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Cephalexin</name>
        <accession>HMDB14707</accession>
      </metabolite>
      <reference>
        <reference_text>Han HK, Rhie JK, Oh DM, Saito G, Hsu CP, Stewart BH, Amidon GL: CHO/hPEPT1 cells overexpressing the human peptide transporter (hPEPT1) as an alternative in vitro model for peptidomimetic drugs. J Pharm Sci. 1999 Mar;88(3):347-50.</reference_text>
        <pubmed_id>10052994</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Cephalexin</name>
        <accession>HMDB14707</accession>
      </metabolite>
      <reference>
        <reference_text>Guo A, Hu P, Balimane PV, Leibach FH, Sinko PJ: Interactions of a nonpeptidic drug, valacyclovir, with the human intestinal peptide transporter (hPEPT1) expressed in a mammalian cell line. J Pharmacol Exp Ther. 1999 Apr;289(1):448-54.</reference_text>
        <pubmed_id>10087037</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Cephalexin</name>
        <accession>HMDB14707</accession>
      </metabolite>
      <reference>
        <reference_text>Luckner P, Brandsch M: Interaction of 31 beta-lactam antibiotics with the H+/peptide symporter PEPT2: analysis of affinity constants and comparison with PEPT1. Eur J Pharm Biopharm. 2005 Jan;59(1):17-24.</reference_text>
        <pubmed_id>15567297</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Cephalexin</name>
        <accession>HMDB14707</accession>
      </metabolite>
      <reference>
        <reference_text>Terada T, Saito H, Mukai M, Inui K: Recognition of beta-lactam antibiotics by rat peptide transporters, PEPT1 and PEPT2, in LLC-PK1 cells. Am J Physiol. 1997 Nov;273(5 Pt 2):F706-11.</reference_text>
        <pubmed_id>9374833</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Cephalexin</name>
        <accession>HMDB14707</accession>
      </metabolite>
      <reference>
        <reference_text>Ganapathy ME, Brandsch M, Prasad PD, Ganapathy V, Leibach FH: Differential recognition of beta -lactam antibiotics by intestinal and renal peptide transporters, PEPT 1 and PEPT 2. J Biol Chem. 1995 Oct 27;270(43):25672-7.</reference_text>
        <pubmed_id>7592745</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Cephalexin</name>
        <accession>HMDB14707</accession>
      </metabolite>
      <reference>
        <reference_text>Tamai I, Nakanishi T, Hayashi K, Terao T, Sai Y, Shiraga T, Miyamoto K, Takeda E, Higashida H, Tsuji A: The predominant contribution of oligopeptide transporter PepT1 to intestinal absorption of beta-lactam antibiotics in the rat small intestine. J Pharm Pharmacol. 1997 Aug;49(8):796-801.</reference_text>
        <pubmed_id>9379359</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Valaciclovir</name>
        <accession>HMDB14716</accession>
      </metabolite>
      <reference>
        <reference_text>Ganapathy ME, Huang W, Wang H, Ganapathy V, Leibach FH: Valacyclovir: a substrate for the intestinal and renal peptide transporters PEPT1 and PEPT2. Biochem Biophys Res Commun. 1998 May 19;246(2):470-5.</reference_text>
        <pubmed_id>9610386</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Valaciclovir</name>
        <accession>HMDB14716</accession>
      </metabolite>
      <reference>
        <reference_text>Han H, de Vrueh RL, Rhie JK, Covitz KM, Smith PL, Lee CP, Oh DM, Sadee W, Amidon GL: 5'-Amino acid esters of antiviral nucleosides, acyclovir, and AZT are absorbed by the intestinal PEPT1 peptide transporter. Pharm Res. 1998 Aug;15(8):1154-9.</reference_text>
        <pubmed_id>9706043</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Valaciclovir</name>
        <accession>HMDB14716</accession>
      </metabolite>
      <reference>
        <reference_text>Balimane PV, Tamai I, Guo A, Nakanishi T, Kitada H, Leibach FH, Tsuji A, Sinko PJ: Direct evidence for peptide transporter (PepT1)-mediated uptake of a nonpeptide prodrug, valacyclovir. Biochem Biophys Res Commun. 1998 Sep 18;250(2):246-51.</reference_text>
        <pubmed_id>9753615</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Valaciclovir</name>
        <accession>HMDB14716</accession>
      </metabolite>
      <reference>
        <reference_text>Sawada K, Terada T, Saito H, Hashimoto Y, Inui KI: Recognition of L-amino acid ester compounds by rat peptide transporters PEPT1 and PEPT2. J Pharmacol Exp Ther. 1999 Nov;291(2):705-9.</reference_text>
        <pubmed_id>10525090</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Valaciclovir</name>
        <accession>HMDB14716</accession>
      </metabolite>
      <reference>
        <reference_text>Balimane P, Sinko P: Effect of ionization on the variable uptake of valacyclovir via the human intestinal peptide transporter (hPepT1) in CHO cells. Biopharm Drug Dispos. 2000 Jul;21(5):165-74.</reference_text>
        <pubmed_id>11180195</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Valaciclovir</name>
        <accession>HMDB14716</accession>
      </metabolite>
      <reference>
        <reference_text>Guo A, Hu P, Balimane PV, Leibach FH, Sinko PJ: Interactions of a nonpeptidic drug, valacyclovir, with the human intestinal peptide transporter (hPEPT1) expressed in a mammalian cell line. J Pharmacol Exp Ther. 1999 Apr;289(1):448-54.</reference_text>
        <pubmed_id>10087037</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Enalapril</name>
        <accession>HMDB14722</accession>
      </metabolite>
      <reference>
        <reference_text>Han H, de Vrueh RL, Rhie JK, Covitz KM, Smith PL, Lee CP, Oh DM, Sadee W, Amidon GL: 5'-Amino acid esters of antiviral nucleosides, acyclovir, and AZT are absorbed by the intestinal PEPT1 peptide transporter. Pharm Res. 1998 Aug;15(8):1154-9.</reference_text>
        <pubmed_id>9706043</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Enalapril</name>
        <accession>HMDB14722</accession>
      </metabolite>
      <reference>
        <reference_text>Han HK, Rhie JK, Oh DM, Saito G, Hsu CP, Stewart BH, Amidon GL: CHO/hPEPT1 cells overexpressing the human peptide transporter (hPEPT1) as an alternative in vitro model for peptidomimetic drugs. J Pharm Sci. 1999 Mar;88(3):347-50.</reference_text>
        <pubmed_id>10052994</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Enalapril</name>
        <accession>HMDB14722</accession>
      </metabolite>
      <reference>
        <reference_text>Temple CS, Boyd CA: Proton-coupled oligopeptide transport by rat renal cortical brush border membrane vesicles: a functional analysis using ACE inhibitors to determine the isoform of the transporter. Biochim Biophys Acta. 1998 Aug 14;1373(1):277-81.</reference_text>
        <pubmed_id>9733984</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Enalapril</name>
        <accession>HMDB14722</accession>
      </metabolite>
      <reference>
        <reference_text>Tsuji A: Transporter-mediated Drug Interactions.  Drug Metab Pharmacokinet. 2002;17(4):253-74.</reference_text>
        <pubmed_id>15618677</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Cefixime</name>
        <accession>HMDB14809</accession>
      </metabolite>
      <reference>
        <reference_text>Wenzel U, Gebert I, Weintraut H, Weber WM, Clauss W, Daniel H: Transport characteristics of differently charged cephalosporin antibiotics in oocytes expressing the cloned intestinal peptide transporter PepT1 and in human intestinal Caco-2 cells. J Pharmacol Exp Ther. 1996 May;277(2):831-9.</reference_text>
        <pubmed_id>8627565</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Cefixime</name>
        <accession>HMDB14809</accession>
      </metabolite>
      <reference>
        <reference_text>Ganapathy ME, Prasad PD, Mackenzie B, Ganapathy V, Leibach FH: Interaction of anionic cephalosporins with the intestinal and renal peptide transporters PEPT 1 and PEPT 2. Biochim Biophys Acta. 1997 Mar 13;1324(2):296-308.</reference_text>
        <pubmed_id>9092716</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Cefixime</name>
        <accession>HMDB14809</accession>
      </metabolite>
      <reference>
        <reference_text>Luckner P, Brandsch M: Interaction of 31 beta-lactam antibiotics with the H+/peptide symporter PEPT2: analysis of affinity constants and comparison with PEPT1. Eur J Pharm Biopharm. 2005 Jan;59(1):17-24.</reference_text>
        <pubmed_id>15567297</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Cefixime</name>
        <accession>HMDB14809</accession>
      </metabolite>
      <reference>
        <reference_text>Terada T, Saito H, Mukai M, Inui K: Characterization of stably transfected kidney epithelial cell line expressing rat H+/peptide cotransporter PEPT1: localization of PEPT1 and transport of beta-lactam antibiotics. J Pharmacol Exp Ther. 1997 Jun;281(3):1415-21.</reference_text>
        <pubmed_id>9190878</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Cefixime</name>
        <accession>HMDB14809</accession>
      </metabolite>
      <reference>
        <reference_text>Terada T, Saito H, Mukai M, Inui K: Recognition of beta-lactam antibiotics by rat peptide transporters, PEPT1 and PEPT2, in LLC-PK1 cells. Am J Physiol. 1997 Nov;273(5 Pt 2):F706-11.</reference_text>
        <pubmed_id>9374833</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Cefixime</name>
        <accession>HMDB14809</accession>
      </metabolite>
      <reference>
        <reference_text>Tsuji A: Transporter-mediated Drug Interactions.  Drug Metab Pharmacokinet. 2002;17(4):253-74.</reference_text>
        <pubmed_id>15618677</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Cefixime</name>
        <accession>HMDB14809</accession>
      </metabolite>
      <reference>
        <reference_text>Tamai I, Nakanishi T, Hayashi K, Terao T, Sai Y, Shiraga T, Miyamoto K, Takeda E, Higashida H, Tsuji A: The predominant contribution of oligopeptide transporter PepT1 to intestinal absorption of beta-lactam antibiotics in the rat small intestine. J Pharm Pharmacol. 1997 Aug;49(8):796-801.</reference_text>
        <pubmed_id>9379359</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>2-Hydroxychlorpropamide</name>
        <accession>HMDB14024</accession>
      </metabolite>
      <reference>
        <reference_text>Terada T, Sawada K, Saito H, Hashimoto Y, Inui K: Inhibitory effect of novel oral hypoglycemic agent nateglinide (AY4166) on peptide transporters PEPT1 and PEPT2. Eur J Pharmacol. 2000 Mar 24;392(1-2):11-7.</reference_text>
        <pubmed_id>10748266</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Moexipril</name>
        <accession>HMDB14829</accession>
      </metabolite>
      <reference>
        <reference_text>Knutter I, Wollesky C, Kottra G, Hahn MG, Fischer W, Zebisch K, Neubert RH, Daniel H, Brandsch M: Transport of angiotensin-converting enzyme inhibitors by H+/peptide transporters revisited. J Pharmacol Exp Ther. 2008 Nov;327(2):432-41. Epub 2008 Aug 19.</reference_text>
        <pubmed_id>18713951</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Oxacillin</name>
        <accession>HMDB14851</accession>
      </metabolite>
      <reference>
        <reference_text>Luckner P, Brandsch M: Interaction of 31 beta-lactam antibiotics with the H+/peptide symporter PEPT2: analysis of affinity constants and comparison with PEPT1. Eur J Pharm Biopharm. 2005 Jan;59(1):17-24.</reference_text>
        <pubmed_id>15567297</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Nateglinide</name>
        <accession>HMDB14869</accession>
      </metabolite>
      <reference>
        <reference_text>Terada T, Sawada K, Saito H, Hashimoto Y, Inui K: Inhibitory effect of novel oral hypoglycemic agent nateglinide (AY4166) on peptide transporters PEPT1 and PEPT2. Eur J Pharmacol. 2000 Mar 24;392(1-2):11-7.</reference_text>
        <pubmed_id>10748266</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Perindopril</name>
        <accession>HMDB14928</accession>
      </metabolite>
      <reference>
        <reference_text>Knutter I, Wollesky C, Kottra G, Hahn MG, Fischer W, Zebisch K, Neubert RH, Daniel H, Brandsch M: Transport of angiotensin-converting enzyme inhibitors by H+/peptide transporters revisited. J Pharmacol Exp Ther. 2008 Nov;327(2):432-41. Epub 2008 Aug 19.</reference_text>
        <pubmed_id>18713951</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Cefaclor</name>
        <accession>HMDB14971</accession>
      </metabolite>
      <reference>
        <reference_text>Han HK, Rhie JK, Oh DM, Saito G, Hsu CP, Stewart BH, Amidon GL: CHO/hPEPT1 cells overexpressing the human peptide transporter (hPEPT1) as an alternative in vitro model for peptidomimetic drugs. J Pharm Sci. 1999 Mar;88(3):347-50.</reference_text>
        <pubmed_id>10052994</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Cefaclor</name>
        <accession>HMDB14971</accession>
      </metabolite>
      <reference>
        <reference_text>Luckner P, Brandsch M: Interaction of 31 beta-lactam antibiotics with the H+/peptide symporter PEPT2: analysis of affinity constants and comparison with PEPT1. Eur J Pharm Biopharm. 2005 Jan;59(1):17-24.</reference_text>
        <pubmed_id>15567297</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Quinapril</name>
        <accession>HMDB15019</accession>
      </metabolite>
      <reference>
        <reference_text>Knutter I, Wollesky C, Kottra G, Hahn MG, Fischer W, Zebisch K, Neubert RH, Daniel H, Brandsch M: Transport of angiotensin-converting enzyme inhibitors by H+/peptide transporters revisited. J Pharmacol Exp Ther. 2008 Nov;327(2):432-41. Epub 2008 Aug 19.</reference_text>
        <pubmed_id>18713951</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Cyclacillin</name>
        <accession>HMDB15135</accession>
      </metabolite>
      <reference>
        <reference_text>Ganapathy ME, Brandsch M, Prasad PD, Ganapathy V, Leibach FH: Differential recognition of beta -lactam antibiotics by intestinal and renal peptide transporters, PEPT 1 and PEPT 2. J Biol Chem. 1995 Oct 27;270(43):25672-7.</reference_text>
        <pubmed_id>7592745</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Cyclacillin</name>
        <accession>HMDB15135</accession>
      </metabolite>
      <reference>
        <reference_text>Luckner P, Brandsch M: Interaction of 31 beta-lactam antibiotics with the H+/peptide symporter PEPT2: analysis of affinity constants and comparison with PEPT1. Eur J Pharm Biopharm. 2005 Jan;59(1):17-24.</reference_text>
        <pubmed_id>15567297</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Cyclacillin</name>
        <accession>HMDB15135</accession>
      </metabolite>
      <reference>
        <reference_text>Terada T, Saito H, Mukai M, Inui K: Recognition of beta-lactam antibiotics by rat peptide transporters, PEPT1 and PEPT2, in LLC-PK1 cells. Am J Physiol. 1997 Nov;273(5 Pt 2):F706-11.</reference_text>
        <pubmed_id>9374833</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Glyburide</name>
        <accession>HMDB15151</accession>
      </metabolite>
      <reference>
        <reference_text>Sawada K, Terada T, Saito H, Hashimoto Y, Inui K: Effects of glibenclamide on glycylsarcosine transport by the rat peptide transporters PEPT1 and PEPT2. Br J Pharmacol. 1999 Nov;128(6):1159-64.</reference_text>
        <pubmed_id>10578127</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Penicillin G</name>
        <accession>HMDB15186</accession>
      </metabolite>
      <reference>
        <reference_text>Luckner P, Brandsch M: Interaction of 31 beta-lactam antibiotics with the H+/peptide symporter PEPT2: analysis of affinity constants and comparison with PEPT1. Eur J Pharm Biopharm. 2005 Jan;59(1):17-24.</reference_text>
        <pubmed_id>15567297</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Penicillin G</name>
        <accession>HMDB15186</accession>
      </metabolite>
      <reference>
        <reference_text>Tsuji A: Transporter-mediated Drug Interactions.  Drug Metab Pharmacokinet. 2002;17(4):253-74.</reference_text>
        <pubmed_id>15618677</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Amoxicillin</name>
        <accession>HMDB15193</accession>
      </metabolite>
      <reference>
        <reference_text>Wenzel U, Gebert I, Weintraut H, Weber WM, Clauss W, Daniel H: Transport characteristics of differently charged cephalosporin antibiotics in oocytes expressing the cloned intestinal peptide transporter PepT1 and in human intestinal Caco-2 cells. J Pharmacol Exp Ther. 1996 May;277(2):831-9.</reference_text>
        <pubmed_id>8627565</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Amoxicillin</name>
        <accession>HMDB15193</accession>
      </metabolite>
      <reference>
        <reference_text>Luckner P, Brandsch M: Interaction of 31 beta-lactam antibiotics with the H+/peptide symporter PEPT2: analysis of affinity constants and comparison with PEPT1. Eur J Pharm Biopharm. 2005 Jan;59(1):17-24.</reference_text>
        <pubmed_id>15567297</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Amoxicillin</name>
        <accession>HMDB15193</accession>
      </metabolite>
      <reference>
        <reference_text>Terada T, Saito H, Mukai M, Inui K: Recognition of beta-lactam antibiotics by rat peptide transporters, PEPT1 and PEPT2, in LLC-PK1 cells. Am J Physiol. 1997 Nov;273(5 Pt 2):F706-11.</reference_text>
        <pubmed_id>9374833</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Cefuroxime</name>
        <accession>HMDB15244</accession>
      </metabolite>
      <reference>
        <reference_text>Luckner P, Brandsch M: Interaction of 31 beta-lactam antibiotics with the H+/peptide symporter PEPT2: analysis of affinity constants and comparison with PEPT1. Eur J Pharm Biopharm. 2005 Jan;59(1):17-24.</reference_text>
        <pubmed_id>15567297</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Tolbutamide</name>
        <accession>HMDB15256</accession>
      </metabolite>
      <reference>
        <reference_text>Terada T, Sawada K, Saito H, Hashimoto Y, Inui K: Inhibitory effect of novel oral hypoglycemic agent nateglinide (AY4166) on peptide transporters PEPT1 and PEPT2. Eur J Pharmacol. 2000 Mar 24;392(1-2):11-7.</reference_text>
        <pubmed_id>10748266</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Cefadroxil</name>
        <accession>HMDB15271</accession>
      </metabolite>
      <reference>
        <reference_text>Ganapathy ME, Brandsch M, Prasad PD, Ganapathy V, Leibach FH: Differential recognition of beta -lactam antibiotics by intestinal and renal peptide transporters, PEPT 1 and PEPT 2. J Biol Chem. 1995 Oct 27;270(43):25672-7.</reference_text>
        <pubmed_id>7592745</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Cefadroxil</name>
        <accession>HMDB15271</accession>
      </metabolite>
      <reference>
        <reference_text>Wenzel U, Gebert I, Weintraut H, Weber WM, Clauss W, Daniel H: Transport characteristics of differently charged cephalosporin antibiotics in oocytes expressing the cloned intestinal peptide transporter PepT1 and in human intestinal Caco-2 cells. J Pharmacol Exp Ther. 1996 May;277(2):831-9.</reference_text>
        <pubmed_id>8627565</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Cefadroxil</name>
        <accession>HMDB15271</accession>
      </metabolite>
      <reference>
        <reference_text>Balimane PV, Tamai I, Guo A, Nakanishi T, Kitada H, Leibach FH, Tsuji A, Sinko PJ: Direct evidence for peptide transporter (PepT1)-mediated uptake of a nonpeptide prodrug, valacyclovir. Biochem Biophys Res Commun. 1998 Sep 18;250(2):246-51.</reference_text>
        <pubmed_id>9753615</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Cefadroxil</name>
        <accession>HMDB15271</accession>
      </metabolite>
      <reference>
        <reference_text>Guo A, Hu P, Balimane PV, Leibach FH, Sinko PJ: Interactions of a nonpeptidic drug, valacyclovir, with the human intestinal peptide transporter (hPEPT1) expressed in a mammalian cell line. J Pharmacol Exp Ther. 1999 Apr;289(1):448-54.</reference_text>
        <pubmed_id>10087037</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Cefadroxil</name>
        <accession>HMDB15271</accession>
      </metabolite>
      <reference>
        <reference_text>Luckner P, Brandsch M: Interaction of 31 beta-lactam antibiotics with the H+/peptide symporter PEPT2: analysis of affinity constants and comparison with PEPT1. Eur J Pharm Biopharm. 2005 Jan;59(1):17-24.</reference_text>
        <pubmed_id>15567297</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Cefadroxil</name>
        <accession>HMDB15271</accession>
      </metabolite>
      <reference>
        <reference_text>Terada T, Saito H, Mukai M, Inui K: Recognition of beta-lactam antibiotics by rat peptide transporters, PEPT1 and PEPT2, in LLC-PK1 cells. Am J Physiol. 1997 Nov;273(5 Pt 2):F706-11.</reference_text>
        <pubmed_id>9374833</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Cefadroxil</name>
        <accession>HMDB15271</accession>
      </metabolite>
      <reference>
        <reference_text>Tsuji A: Transporter-mediated Drug Interactions.  Drug Metab Pharmacokinet. 2002;17(4):253-74.</reference_text>
        <pubmed_id>15618677</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Cefadroxil</name>
        <accession>HMDB15271</accession>
      </metabolite>
      <reference>
        <reference_text>Tamai I, Nakanishi T, Hayashi K, Terao T, Sai Y, Shiraga T, Miyamoto K, Takeda E, Higashida H, Tsuji A: The predominant contribution of oligopeptide transporter PepT1 to intestinal absorption of beta-lactam antibiotics in the rat small intestine. J Pharm Pharmacol. 1997 Aug;49(8):796-801.</reference_text>
        <pubmed_id>9379359</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Cloxacillin</name>
        <accession>HMDB15278</accession>
      </metabolite>
      <reference>
        <reference_text>Luckner P, Brandsch M: Interaction of 31 beta-lactam antibiotics with the H+/peptide symporter PEPT2: analysis of affinity constants and comparison with PEPT1. Eur J Pharm Biopharm. 2005 Jan;59(1):17-24.</reference_text>
        <pubmed_id>15567297</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Captopril</name>
        <accession>HMDB15328</accession>
      </metabolite>
      <reference>
        <reference_text>Watanabe K, Sawano T, Terada K, Endo T, Sakata M, Sato J: Studies on intestinal absorption of sulpiride (1): carrier-mediated uptake of sulpiride in the human intestinal cell line Caco-2. Biol Pharm Bull. 2002 Jul;25(7):885-90.</reference_text>
        <pubmed_id>12132663</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Captopril</name>
        <accession>HMDB15328</accession>
      </metabolite>
      <reference>
        <reference_text>Temple CS, Boyd CA: Proton-coupled oligopeptide transport by rat renal cortical brush border membrane vesicles: a functional analysis using ACE inhibitors to determine the isoform of the transporter. Biochim Biophys Acta. 1998 Aug 14;1373(1):277-81.</reference_text>
        <pubmed_id>9733984</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Ceftriaxone</name>
        <accession>HMDB15343</accession>
      </metabolite>
      <reference>
        <reference_text>Luckner P, Brandsch M: Interaction of 31 beta-lactam antibiotics with the H+/peptide symporter PEPT2: analysis of affinity constants and comparison with PEPT1. Eur J Pharm Biopharm. 2005 Jan;59(1):17-24.</reference_text>
        <pubmed_id>15567297</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>L-Dopa</name>
        <accession>HMDB00181</accession>
      </metabolite>
      <reference>
        <reference_text>Han HK, Rhie JK, Oh DM, Saito G, Hsu CP, Stewart BH, Amidon GL: CHO/hPEPT1 cells overexpressing the human peptide transporter (hPEPT1) as an alternative in vitro model for peptidomimetic drugs. J Pharm Sci. 1999 Mar;88(3):347-50.</reference_text>
        <pubmed_id>10052994</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Ceftizoxime</name>
        <accession>HMDB15427</accession>
      </metabolite>
      <reference>
        <reference_text>Tsuji A: Transporter-mediated Drug Interactions.  Drug Metab Pharmacokinet. 2002;17(4):253-74.</reference_text>
        <pubmed_id>15618677</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Cefradine</name>
        <accession>HMDB15428</accession>
      </metabolite>
      <reference>
        <reference_text>Han H, de Vrueh RL, Rhie JK, Covitz KM, Smith PL, Lee CP, Oh DM, Sadee W, Amidon GL: 5'-Amino acid esters of antiviral nucleosides, acyclovir, and AZT are absorbed by the intestinal PEPT1 peptide transporter. Pharm Res. 1998 Aug;15(8):1154-9.</reference_text>
        <pubmed_id>9706043</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Cefradine</name>
        <accession>HMDB15428</accession>
      </metabolite>
      <reference>
        <reference_text>Han HK, Rhie JK, Oh DM, Saito G, Hsu CP, Stewart BH, Amidon GL: CHO/hPEPT1 cells overexpressing the human peptide transporter (hPEPT1) as an alternative in vitro model for peptidomimetic drugs. J Pharm Sci. 1999 Mar;88(3):347-50.</reference_text>
        <pubmed_id>10052994</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Cefradine</name>
        <accession>HMDB15428</accession>
      </metabolite>
      <reference>
        <reference_text>Saito H, Okuda M, Terada T, Sasaki S, Inui K: Cloning and characterization of a rat H+/peptide cotransporter mediating absorption of beta-lactam antibiotics in the intestine and kidney. J Pharmacol Exp Ther. 1995 Dec;275(3):1631-7.</reference_text>
        <pubmed_id>8531138</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Cefradine</name>
        <accession>HMDB15428</accession>
      </metabolite>
      <reference>
        <reference_text>Terada T, Saito H, Mukai M, Inui K: Recognition of beta-lactam antibiotics by rat peptide transporters, PEPT1 and PEPT2, in LLC-PK1 cells. Am J Physiol. 1997 Nov;273(5 Pt 2):F706-11.</reference_text>
        <pubmed_id>9374833</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Cefradine</name>
        <accession>HMDB15428</accession>
      </metabolite>
      <reference>
        <reference_text>Terada T, Saito H, Mukai M, Inui K: Characterization of stably transfected kidney epithelial cell line expressing rat H+/peptide cotransporter PEPT1: localization of PEPT1 and transport of beta-lactam antibiotics. J Pharmacol Exp Ther. 1997 Jun;281(3):1415-21.</reference_text>
        <pubmed_id>9190878</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Cilazapril</name>
        <accession>HMDB15433</accession>
      </metabolite>
      <reference>
        <reference_text>Knutter I, Wollesky C, Kottra G, Hahn MG, Fischer W, Zebisch K, Neubert RH, Daniel H, Brandsch M: Transport of angiotensin-converting enzyme inhibitors by H+/peptide transporters revisited. J Pharmacol Exp Ther. 2008 Nov;327(2):432-41. Epub 2008 Aug 19.</reference_text>
        <pubmed_id>18713951</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Spirapril</name>
        <accession>HMDB15438</accession>
      </metabolite>
      <reference>
        <reference_text>Knutter I, Wollesky C, Kottra G, Hahn MG, Fischer W, Zebisch K, Neubert RH, Daniel H, Brandsch M: Transport of angiotensin-converting enzyme inhibitors by H+/peptide transporters revisited. J Pharmacol Exp Ther. 2008 Nov;327(2):432-41. Epub 2008 Aug 19.</reference_text>
        <pubmed_id>18713951</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Cefepime</name>
        <accession>HMDB15483</accession>
      </metabolite>
      <reference>
        <reference_text>Ganapathy ME, Huang W, Rajan DP, Carter AL, Sugawara M, Iseki K, Leibach FH, Ganapathy V: beta-lactam antibiotics as substrates for OCTN2, an organic cation/carnitine transporter. J Biol Chem. 2000 Jan 21;275(3):1699-707.</reference_text>
        <pubmed_id>10636865</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Cefepime</name>
        <accession>HMDB15483</accession>
      </metabolite>
      <reference>
        <reference_text>Luckner P, Brandsch M: Interaction of 31 beta-lactam antibiotics with the H+/peptide symporter PEPT2: analysis of affinity constants and comparison with PEPT1. Eur J Pharm Biopharm. 2005 Jan;59(1):17-24.</reference_text>
        <pubmed_id>15567297</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Ceftibuten</name>
        <accession>HMDB15485</accession>
      </metabolite>
      <reference>
        <reference_text>Ganapathy ME, Prasad PD, Mackenzie B, Ganapathy V, Leibach FH: Interaction of anionic cephalosporins with the intestinal and renal peptide transporters PEPT 1 and PEPT 2. Biochim Biophys Acta. 1997 Mar 13;1324(2):296-308.</reference_text>
        <pubmed_id>9092716</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Ceftibuten</name>
        <accession>HMDB15485</accession>
      </metabolite>
      <reference>
        <reference_text>Luckner P, Brandsch M: Interaction of 31 beta-lactam antibiotics with the H+/peptide symporter PEPT2: analysis of affinity constants and comparison with PEPT1. Eur J Pharm Biopharm. 2005 Jan;59(1):17-24.</reference_text>
        <pubmed_id>15567297</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Ceftibuten</name>
        <accession>HMDB15485</accession>
      </metabolite>
      <reference>
        <reference_text>Saito H, Okuda M, Terada T, Sasaki S, Inui K: Cloning and characterization of a rat H+/peptide cotransporter mediating absorption of beta-lactam antibiotics in the intestine and kidney. J Pharmacol Exp Ther. 1995 Dec;275(3):1631-7.</reference_text>
        <pubmed_id>8531138</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Ceftibuten</name>
        <accession>HMDB15485</accession>
      </metabolite>
      <reference>
        <reference_text>Terada T, Saito H, Mukai M, Inui K: Characterization of stably transfected kidney epithelial cell line expressing rat H+/peptide cotransporter PEPT1: localization of PEPT1 and transport of beta-lactam antibiotics. J Pharmacol Exp Ther. 1997 Jun;281(3):1415-21.</reference_text>
        <pubmed_id>9190878</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Ceftibuten</name>
        <accession>HMDB15485</accession>
      </metabolite>
      <reference>
        <reference_text>Terada T, Saito H, Mukai M, Inui K: Recognition of beta-lactam antibiotics by rat peptide transporters, PEPT1 and PEPT2, in LLC-PK1 cells. Am J Physiol. 1997 Nov;273(5 Pt 2):F706-11.</reference_text>
        <pubmed_id>9374833</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Ceftibuten</name>
        <accession>HMDB15485</accession>
      </metabolite>
      <reference>
        <reference_text>Tsuji A: Transporter-mediated Drug Interactions.  Drug Metab Pharmacokinet. 2002;17(4):253-74.</reference_text>
        <pubmed_id>15618677</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Azidocillin</name>
        <accession>HMDB15685</accession>
      </metabolite>
      <reference>
        <reference_text>Covitz KM, Amidon GL, Sadee W: Human dipeptide transporter, hPEPT1, stably transfected into Chinese hamster ovary cells. Pharm Res. 1996 Nov;13(11):1631-4.</reference_text>
        <pubmed_id>8956326</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Azidocillin</name>
        <accession>HMDB15685</accession>
      </metabolite>
      <reference>
        <reference_text>Guo A, Hu P, Balimane PV, Leibach FH, Sinko PJ: Interactions of a nonpeptidic drug, valacyclovir, with the human intestinal peptide transporter (hPEPT1) expressed in a mammalian cell line. J Pharmacol Exp Ther. 1999 Apr;289(1):448-54.</reference_text>
        <pubmed_id>10087037</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Azidocillin</name>
        <accession>HMDB15685</accession>
      </metabolite>
      <reference>
        <reference_text>Luckner P, Brandsch M: Interaction of 31 beta-lactam antibiotics with the H+/peptide symporter PEPT2: analysis of affinity constants and comparison with PEPT1. Eur J Pharm Biopharm. 2005 Jan;59(1):17-24.</reference_text>
        <pubmed_id>15567297</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Azidocillin</name>
        <accession>HMDB15685</accession>
      </metabolite>
      <reference>
        <reference_text>Terada T, Saito H, Mukai M, Inui K: Recognition of beta-lactam antibiotics by rat peptide transporters, PEPT1 and PEPT2, in LLC-PK1 cells. Am J Physiol. 1997 Nov;273(5 Pt 2):F706-11.</reference_text>
        <pubmed_id>9374833</pubmed_id>
      </reference>
    </metabolite_reference>
  </metabolite_references>
</protein>
